Reference: https://www.nmn.com/news/nmn-suppresses-the-progression-of-hearing-loss-new-research-from-japan-show
A recent study conducted by researchers at the Wellness Science Laboratory in Japan has demonstrated that nicotinamide mononucleotide (NMN) supplementation can prevent age-related hearing loss in mice.
The study observed that older mice exhibited higher auditory brainstem response (ABR) thresholds compared to younger mice, indicating hearing impairment. However, when 12-week-old mice were administered NMN at a dose of 500 mg/kg/day for 13 weeks, they maintained significantly lower ABR thresholds, suggesting that NMN effectively suppressed the progression of hearing loss.
Interestingly, the researchers did not observe a decline in NAD+ levels within the cochlea of the aged mice, which contrasts with previous studies showing reduced NAD+ levels in older mice. This discrepancy may be due to the relatively young age of the "aged" mice in the current study.
Additionally, NMN supplementation led to changes in gene expression related to ion homeostasis in the cochlea, implying that NMN may counteract age-related dysregulation of essential ions like iron and zinc in the inner ear.
While these findings are promising, translating them to human applications requires caution. Previous human studies have not shown significant improvements in hearing capacity with NMN supplementation, nor a correlation between blood NAD+ levels and hearing ability.
Therefore, further research is necessary to determine whether NMN can effectively mitigate age-related hearing loss in humans.
